Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study

Daniel J. Wallace, Caroline Gordon, Michelle Petri et al.|Annals of the Rheumatic Diseases|2013

Cited by 340